Analytical Data
-
Gene name
TINAG
- Application
-
Alternative Names
TIN1; TIN2; TIN-AG
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UJW2
-
Expression Region
Met1~Pro476
-
Molecular Weight
58Da
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TINAG (Tissue Inhibitor of Metalloproteinases 3) is a crucial protein that plays a significant role in various biological processes, including tissue remodeling and cell migration. It is particularly known for its involvement in the regulation of extracellular matrix components and metalloproteinases, which are vital for maintaining tissue homeostasis. Recent studies have highlighted its importance in pathological conditions, including cancer metastasis and fibrosis, making it a promising target for therapeutic interventions. The understanding of TINAG's structure and function has advanced through recombinant protein technologies, which allow for the production of TINAG in a controlled environment. Research focuses on elucidating TINAG's mechanism of action in cellular signaling pathways and its interactions with other proteins. Investigating TINAG's potential as a biomarker for disease progression and treatment response is also a growing area of interest. As the demand for targeted therapies increases, the development of TINAG-based strategies could offer novel approaches in the fields of oncology and regenerative medicine. Understanding TINAG's role at the molecular level is essential for harnessing its therapeutic potential, thus paving the way for innovative treatments that could improve patient outcomes in various diseases.
